nach oben

International Journal of Clinical Oncology

Erschienen in:

05.10.2018 | Special Article

Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer

verfasst von: Yasuhiko Ebina, Mikio Mikami, Satoru Nagase, Tsutomu Tabata, Masanori Kaneuchi, Hironori Tashiro, Masaki Mandai, Takayuki Enomoto, Yoichi Kobayashi, Hidetaka Katabuchi, Nobuo Yaegashi, Yasuhiro Udagawa, Daisuke Aoki

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2017 for the Treatment of Uterine Cervical Cancer are for the purpose of providing standard treatment strategies for cervical cancer, indicating treatment methods currently considered appropriate for cervical cancer, minimizing variances in treatment methods among institutions, improving the safety of treatment and prognosis of diseases, reducing the economic and psychosomatic burden of patients by promoting performance of appropriate treatment, and enhancing mutual understanding between patients and healthcare professionals. The guidelines were prepared through consensus of the JSGO Guideline Committee, based on careful review of evidence gathered through the literature searches and in view of the medical health insurance system and actual clinical practice situations in Japan. The guidelines comprise eight chapters and five algorithms. The main features of the 2017 revision are as follows: (1) evidence was collected using a search formula and with cooperation of the Japan Library Association. The bibliographical search formula was placed at the end of the book; (2) regarding clinical questions (CQs) where evidence or clinical inspection in Japan was lacking, opinions of the Guidelines Committee were described as “proposals for future directions”; (3) cervical intraepithelial neoplasia (CIN) 3 and adenocarcinoma in situ (AIS) were treated as a cervical precancerous lesion; (4) the CQs of endoscopic surgery, radical trachelectomy, and sentinel node biopsy were newly added in Chapter 3, “primary treatment for stage IB–II cervical cancer”; and (5) the CQ about hormone replacement therapy after cancer treatment was newly established. Each recommendation is accompanied by a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here, we present the English version of the JSGO Guidelines 2017 for the Treatment of Uterine Cervical Cancer.

National Cancer Center, Japan (2016) Cancer registry and statistics. Ministry of Health, Labour and Welfare, Tokyo

Nagase S, Inoue Y, Umesaki N et al (2010) Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. Int J Clin Oncol 15:117–124CrossRefPubMed

Ebina Y, Yaegashi N, Katabuchi H et al (2015) Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer. Int J Clin Oncol 20:240–248CrossRefPubMed

Ariyoshi H (2002) Guideline for correct use of antineoplastic agents (draft). General theory. Gan To Kagaku Ryoho 29:970–977PubMed

Ochiai K, Okamoto A, Katsumata N (2002) Guidelines for proper use of antineoplastic agents. Gynecologic cancer. Gan To Kagaku Ryoho 29:1047–1054PubMed

Fukui T, Yoshida M, Yamaguchi N et al (2007) Minds handbook on preparation of treatment guidelines 2007. Igaku Shoin, Tokyo

Yamaguchi N, Morizane T, Kojimahara N et al (2014) Minds handbook on preparation of treatment guidelines 2014. Igaku Shoin, Tokyo

Stoler M, Bergeron C, Colgan TJ et al (2014) Squmous cell tumours and precursors. In: Kurman RJ, Carcangiu ML, Herrington CS et al (ed) World Health Organization classification of tumours, 4th edn. Tumours of Female Reproductive Organs. Lyon, IARC Press, Lyon, pp 172–182

Japanese Society of Obstetrics and Gynecology, Japan Society of Pathology (2017) The general rules for clinicaland pathological management of uterine cervical cancer, pathological edition, 4th edn. Kanehara-shuppan, Tokyo

10.

van Meurs H, Visser O, Buist MR et al (2009) Frequency of pelvic lymph node metastases and parametrial involvement in stage IA2 cervical cancer: a population-based study and literature review. Int J Gynecol Cancer 19:21–26CrossRefPubMed

11.

Katabuchi H (2016) Gynecologic cancer comittee report in 2014. Acta Obstet Gynaecol Jpn 68:1117–1160

12.

Cervical Cancer Guideline (Version 1) (2016) NCCN clinical practice guidelines in oncology

13.

Long Y, Yao DS, Pan XW et al (2014) Clinical efficacy and safety of nerve-sparing radical hysterectomy for cervical cancer: a systematic review and meta-analysis. PLoS One 9:e94116CrossRefPubMedPubMedCentral

14.

Roh JW, Lee DO, Suh DH et al (2015) Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial. J Gynecol Oncol 26:90–99CrossRefPubMedPubMedCentral

15.

Ramirez PT, Jhingran A, Macapinlac HA et al (2011) Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 117:1928–1934CrossRefPubMed

16.

Cosin JA, Fowler JM, Chen MD et al (1998) Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. Cancer 82:2241–2248CrossRefPubMed

17.

Brockbank E, Kokka F, Bryant A et al (2013) Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer. Cochrane Database Syst Rev 2013:CD008217

18.

Sevin BU, Nadji M, Lampe B et al (1995) Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer 76:1978–1986CrossRefPubMed

19.

Lin HH, Cheng WF, Chan KW et al (1996) Risk factors for recurrence in patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. Obstet Gynecol 88:274–279CrossRefPubMed

20.

Roman LD, Felix JC, Muderspach LI et al (1998) Influence of quantity of lymph-vascular space invasion on the risk of nodal metastases in women with early-stage squamous cancer of the cervix. Gynecol Oncol 68:220–225CrossRefPubMed

21.

Comerci G, Bolger BS, Flannelly G et al (1998) Prognostic factors in surgically treated stage IB-IIB carcinoma of the cervix with negative lymph nodes. Int J Gynecol Cancer 8:23–26CrossRefPubMed

22.

Kim SM, Choi HS, Byun JS (2000) Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer 10:305–312CrossRefPubMed

23.

Trattner M, Graf AH, Lax S et al (2001) Prognostic factors in surgically treated stage Ib-IIb cervical carcinomas with special emphasis on the importance of tumor volume. Gynecol Oncol 82:11–16CrossRefPubMed

24.

Takeda N, Sakuragi N, Takeda M et al (2002) Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand 81:1144–1151CrossRefPubMed

25.

Morice P, Piovesan P, Rey A et al (2003) Prognostic value of lymphovascular space invasion determined with hematoxylin-eosin staining in early stage cervical carcinoma: results of a multivariate analysis. Ann Oncol 14:1511–1517CrossRefPubMed

26.

Rutledge TL, Kamelle SA, Tillmanns TD et al (2004) A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol 95:70–76CrossRefPubMed

27.

Chen SW, Liang JA, Yang SN et al (2004) Early stage cervical cancer with negative pelvic lymph nodes: pattern of failure and complication following radical hysterectomy and adjuvant radiotherapy. Eur J Gynaecol Oncol 25:81–86PubMed

28.

Delgado G, Bundy B, Zaino R et al (1990) Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 38:352–357CrossRef

29.

Lai CH, Hong JH, Hsueh S et al (1999) Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases. Cancer 85:1537–1546CrossRefPubMed

30.

Japanese Society of Obstetrics and Gynecology, Japan Society of Pathology (2012) The general rules for clinical and pathological management of uterine cervical cancer, 3rd edn. Kanehara-shuppan, Tokyo

31.

Japanese Society for Radiation Oncology (2012) Guidelines of radiotherapy treatment planning 2012. Kanehara-shuppan, Tokyo

32.

Small W Jr., Mell LK, Anderson P et al (2008) Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 71:428–434CrossRefPubMed

33.

Japan Clinical Oncology Group, Toita T, Ohno T et al (2010) A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol 40: 456–463CrossRef

34.

Perez CA, Kavanagh BD (2008) Uterine cervix. In: Perez CA, Brady LW (eds) Principles and practice of radiation oncology, 5th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1800–1915

35.

Mundt AJ, Mell LK, Roeske JC (2003) Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 56:1354–1360CrossRefPubMed

36.

Jhingran A (2006) Potential advantages of intensity-modulated radiation therapy in gynecologic malignancies. Semin Radiat Oncol 16:144–151CrossRefPubMed

37.

Chen MF, Tseng CJ, Tseng CC et al (2007) Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 67:1438–1444CrossRefPubMed

38.

Klopp AH, Moughan J, Portelance L et al (2016) Pilot study of a computed tomography-compatible shielded intracavitary brachytherapy applicator for treatment of cervical cancer. Pract Radiat Oncol 3:115–123CrossRef

39.

Murakami N, Okamoto H, Kasamatsu T et al (2014) A dosimetric analysis of intensity-modulated radiation therapy with bone marrow sparing for cervical cancer. Anticancer Res 34:5091–5098PubMed

40.

Rotman M, Pajak TF, Choi K et al (1995) Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79 – 20. JAMA 274:387–393CrossRefPubMed

41.

Haie C, Pejovic MH, Gerbaulet A et al (1988) Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol 11:101–112CrossRefPubMed

42.

Toita T, Kitagawa R, Hamano T et al (2012) Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol Oncol 126:211–216CrossRefPubMed

43.

Kato S, Ohno T, Thephamongkhol K et al (2010) Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia. Int J Radiat Oncol Biol Phys 77:751–757CrossRefPubMed

44.

Toita T, Moromizato H, Ogawa K et al (2005) Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer. Gynecol Oncol 96:665–670CrossRefPubMed

45.

Sakata K, Sakurai H, Suzuki et al (2008) Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: study of JROSG (Japan Radiation Oncology Study Group). Acta Oncol 47:434–441CrossRefPubMed

46.

Monk BJ, Sill MW, McMeekin DS et al (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:4649–4655CrossRefPubMedPubMedCentral

47.

Moore KN, Herzog TJ, Lewin S et al (2007) A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 105:299–303CrossRefPubMed

48.

Kitagawa R, Katsumata N, Shibata T et al (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33:2129–2135CrossRefPubMed

49.

Grigsby PW (2005) Radiotherapy for pelvic recurrence after radical hysterectomy for cervical cancer. Radiat Med 23:327–330PubMed

50.

Thomas GM, Dembo AJ, Myhr T et al (1993) Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer 3:193–198CrossRefPubMed

51.

Ito H, Shigematsu N, Kawada T et al (1997) Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy. Gynecol Oncol 67:154–161CrossRefPubMed

52.

Noda K, Ikeda M, Yakushiji M et al (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus]. Gan To Kagaku Ryoho 19:885–892PubMed

53.

Kato T, Nishimura H, Yakushiji M et al (1992) Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Gan To Kagaku Ryoho 19:695–701PubMed

54.

Tsuda H, Hashiguchi Y, Nishimura S et al (2004) Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 91:1032–1037CrossRefPubMedPubMedCentral

55.

Takekuma M, Hirashima Y, Ito K et al (2012) Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study. Gynecol Oncol 126:341–345CrossRefPubMed

56.

Donegan WL (1983) Cancer and pregnancy. CA Cancer J Clin 33:194–214CrossRefPubMed

57.

Abe Y, Ito K, Okamura C et al (2004) Cervical cytologic examination during physical checkup of pregnant women: cervical cancer screening in women under the age of thirty. Tohoku J Exp Med 204:221–228CrossRefPubMed

58.

Zemlickis D, Lishner M, Degendorfer P et al (1991) Maternal and fetal outcome after invasive cervical cancer in pregnancy. J Clin Oncol 9:1956–1961CrossRefPubMed

59.

Morice P, Uzan C, Gouy S et al (2012) Gynaecological cancers in pregnancy. Lancet 379:558–569CrossRefPubMed

60.

Lanceley A, Fiander A, McCormack et al (2013) Followup protocols for women with cervical cancer after primary treatment. Cochrane Database Syst Rev 2013:CD008767

61.

Elit L, Fyles AW, Devries MC et al (2009) Follow-up for women after treatment for cervical cancer: a systematic review. Gynecol Oncol 114:528–535CrossRefPubMed

62.

Salani R, Backes FJ, Fung MF et al (2011) Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 204:466–478CrossRefPubMed

63.

Matsuura Y, Kawagoe T, Toki N et al (2006) Long-standing complications after treatment for cancer of the uterine cervix–clinical significance of medical examination at 5 years after treatment. Int J Gynecol Cancer 16:294–297CrossRefPubMed

64.

Greimel ER, Winter R, Kapp KS et al (2009) Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology 18:476–482CrossRefPubMed

65.

Park SY, Bae DS, Nam JH et al (2007) Quality of life and sexual problems in disease-free survivors of cervical cancer compared with the general population. Cancer 110:2716–2725CrossRefPubMed

Titel: Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer
verfasst von: Yasuhiko Ebina
Mikio Mikami
Satoru Nagase
Tsutomu Tabata
Masanori Kaneuchi
Hironori Tashiro
Masaki Mandai
Takayuki Enomoto
Yoichi Kobayashi
Hidetaka Katabuchi
Nobuo Yaegashi
Yasuhiro Udagawa
Daisuke Aoki
Publikationsdatum: 05.10.2018
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 1/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1351-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Recognition and attitudes of Japanese hematologists on sperm banking before chemotherapy: present status from nationwide questionnaire survey

Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma

Clinical Practice Guidelines for Fertility Preservation in Pediatric, Adolescent, and Young Adults with Cancer

Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma

Does tumour effraction during robotic partial nephrectomy have any impact on recurrence?

Long-term influence of adjuvant breast radiotherapy on cognitive function in breast cancer patients treated with conservation therapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie